Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

By M. Attal, J. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Yakoub Agha, J. Bourhis, L. Garderet, B. Pégourié and 11 more. Blood, 2006

675 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/0278f51153f8501f746c3fd691607794c71d0d79

Citations in the corpus

• Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. (2007, neutral): “Translocation ( 11 ;14) 37/223 (17%) 11/95 (12%) 11/58 (19%) 15/70 (21%)”